Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia



Status:Recruiting
Conditions:Other Indications, Blood Cancer
Therapuetic Areas:Oncology, Other
Healthy:No
Age Range:30 - 70
Updated:2/16/2019
Start Date:December 23, 2013

Use our guide to learn which trials are right for you!

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how
well it works compared to induction chemotherapy alone in treating patients with newly
diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase
(ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as
blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not
yet known whether combination chemotherapy is more effective with or without blinatumomab in
treating newly diagnosed acute lymphoblastic leukemia.

PRIMARY OBJECTIVES:

I. To compare the overall survival (OS) of blinatumomab in conjunction with chemotherapy to
chemotherapy alone in patients with BCR-ABL-negative B cell precursor acute lymphoblastic
leukemia (ALL) who are minimal residual disease (MRD) positive after induction and
intensification chemotherapy, based on multiparameter flow cytometric (MFC) assessment of
residual blasts.

II. If superiority of blinatumomab in the MRD positive group is shown, to compare the OS of
blinatumomab in conjunction with chemotherapy to chemotherapy alone in patients with
BCR-ABL-negative B cell precursor ALL who are MRD negative after induction and
intensification chemotherapy, based on MFC assessment of residual blasts.

III. If superiority of blinatumomab in the MRD positive group is not shown, to compare the OS
of blinatumomab in conjunction with chemotherapy to chemotherapy alone in the overall
population of patients with BCR-ABL-negative B cell precursor ALL.

SECONDARY OBJECTIVES:

I. To compare the relapse-free survival (RFS) of blinatumomab in conjunction with
chemotherapy to chemotherapy alone in MRD positive patients, MRD negative patients and
overall population after induction and intensification chemotherapy.

II. To determine if blinatumomab can convert patients who are MRD positive by MFC assessment
of residual blasts after induction and intensification chemotherapy to MRD negativity.

III. To assess the toxicities of blinatumomab in this patient population. IV. To assess the
toxicities of the modified E2993 chemotherapy regimen in this patient population.

V. To describe the outcome of patients who proceed to allogeneic blood or marrow transplant
after treatment with or without blinatumomab.

TERTIARY OBJECTIVES:

I. To determine differences in MRD kinetics among patients with the BCR/ABL1-like B-lineage
ALL, and assess the efficacy of blinatumomab in each molecular subgroup.

II. To evaluate the incidence of anti-blinatumomab antibody formation.

OUTLINE:

INDUCTION CHEMOTHERAPY: Patients receive cytarabine intrathecally (IT) on day 1; daunorubicin
hydrochloride intravenously (IV) over 10-15 minutes on days 1, 8, 15, and 22; vincristine
sulfate IV on days 1, 8, 15, and 22; dexamethasone orally (PO) daily on days 1-7 (and 15-21
for patients age < 55 years only); methotrexate IT on day 14; pegaspargase intramuscularly
(IM) or IV on day 18 (patients age =< 55 years); and CD20 positive patients may optionally
receive rituximab IV on day 8 and 15. Beginning on day 29, patients with absolute neutrophil
count (ANC) >= 0.75 x 10^9/L and platelets > 75 x 10^9/L (patients with delayed hematologic
recovery) (patients with residual disease that is delaying count begin treatment immediately)
receive cyclophosphamide IV over 30 minutes on days 1 and 29, cytarabine IV over 30 minutes
or subcutaneously (SC) on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO on days 1-14,
29-42, pegaspargase IM or IV on day 15 (patients age < 55 years), patients receiving
treatment for central nervous system (CNS) 2 or 3 leukemia in course 1 receive methotrexate
IT on days 1, 8, 15, and 22, and CD20 positive patients may optionally receive rituximab IV
on days 8 and 15.

INTENSIFICATION THERAPY: Beginning 4 weeks after the completion of course 2 of induction
therapy, patients receive intensification therapy comprising high-dose methotrexate IV over 2
hours on days 1 and 8, and pegaspargase IM or IV on day 9.

Patients are then randomized to 1 of 2 treatment arms.

Patients randomized to the blinatumomab group receive blinatumomab IV continuously on days
1-28. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or
unacceptable toxicity. Patients may then undergo allogeneic stem cell transplant (SCT) or
proceed to consolidation therapy per investigator discretion.

CONSOLIDATION THERAPY: Beginning after the second course of blinatumomab (patients randomized
to the blinatumomab group) or after intensification therapy (patients not randomized to
blinatumomab), patients receive cytarabine IV over 30 minutes or SC on days 1-5, etoposide IV
over 1 hour on days 1-5, methotrexate IT on day 1, and pegaspargase IM or IV on day 5, and
CD20 positive patients may optionally receive rituximab IV on day 5. Beginning 4 weeks from
day 1 of course 1, patients receive cytarabine, etoposide, methotrexate, and CD20 positive
patients may receive rituximab as in course 1. Beginning 4 weeks from day 1 of course 2,
patients receive daunorubicin hydrochloride IV over 10-15 minutes on day 1, 8, 15, and 22;
vincristine sulfate IV on days 1, 8, 15, and 22; dexamethasone PO daily on days 1-7 (and
15-21 for patients age < 55 years); methotrexate IT on day 2; cyclophosphamide PO or IV over
30 minutes on day 29; cytarabine IV over 30 minutes or SC on days 30-33 and 37-40;
mercaptopurine PO on days 29-42 and CD20 positive patients may receive rituximab on day 8.
Beginning 8 weeks from day 1 of course 3, patients receive cytarabine, etoposide,
methotrexate, and CD20 positive patients may optionally receive rituximab as in course 1.
Patients randomized to blinatumomab repeat course 4 and then receive blinatumomab IV
continuously on days 1-28.

MAINTENANCE THERAPY: Within 12 weeks after beginning last course of consolidation therapy,
patients receive mercaptopurine PO daily, methotrexate PO or IV over 6 hours once weekly for
2.5 years, vincristine sulfate IV on day 1 every 3 months, prednisone PO on days 1-5 every 3
months, and methotrexate IT on day 1 every 3 months. Treatment continues for up to 2.5 years
in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then every 12 months for 5 years.

Inclusion Criteria:

- PRE-REGISTRATION

- Diagnostic bone marrow and peripheral blood specimens must be submitted for
immunophenotyping and selected molecular testing, and the establishment of BCR/ABL
status; testing will be performed by the Eastern Cooperative Oncology Group
(ECOG)-American College of Radiation Imaging Network (ACRIN) Leukemia Translational
Research Laboratory (LTRL) and reported to the institution

- NOTE: IT IS ESSENTIAL THAT A SAMPLE CONTAINING SUFFICIENT BLAST CELLS BE
SUBMITTED TO THE ECOG-ACRIN LTRL AT BASELINE SO THAT SUBSEQUENT BONE MARROW
ASSESSMENTS OF MRD CAN BE DONE; IN ADDITION TO ALLOWING THE LTRL TO CONFIRM
ELIGIBILITY BASED ON BLAST CELL IMMUNOPHENOTYPE AND BCR/ABL STATUS, IT IS ALSO
IMPERATIVE THAT AN ADEQUATE NUMBER OF BLASTS BE BANKED FOR ANALYSIS BY DRS
MULLIGHAN/WILLMAN. WITHOUT ADEQUATE BASELINE SAMPLES, PATIENTS WILL NOT BE ABLE
TO BE TREATED AND RANDOMIZED ON THIS PROTOCOL; IF A BONE MARROW ASPIRATE IS NOT
AVAILABLE FOR LTRL SUBMISSION AT BASELINE, IT IS IMPERATIVE THAT DR PAIETTA FROM
THE LTRL IS CALLED TO DISCUSS THE PERIPHERAL BLOOD WBC AND BLAST COUNT BEFORE
BLOOD ONLY IS SUBMITTED

- NOTE: Hydroxyurea can be given for up to 5 days prior to initiation of protocol
therapy for control of leukocyte count and/or other symptoms or signs;
corticosteroids can be given after pre-registration to the protocol and
submission of baseline marrow and blood samples for control of leukocyte count
and/or other symptoms or signs prior to initiation of protocol therapy if needed;
if corticosteroids are given prior to pre-registration, contact the study chair
as the patient may still be eligible to participate

- INDUCTION ELIGIBILITY CRITERIA-STEP 1

- New diagnosis of B lineage ALL must be made upon bone marrow or peripheral blood
immunophenotyping; cases with myeloid antigen expression, but unequivocal lymphoid
immunophenotype, are eligible

- Mature B ALL (Burkitt's-like leukemia) is excluded from enrollment in this trial;
pre-study bone marrow biopsy and aspirate must be completed =< 1 week prior to
registration

- Negativity for the Philadelphia chromosome must be established by conventional
cytogenetics, fluorescence in situ hybridization (FISH) and/or polymerase chain
reaction (PCR); patients who are negative for the Philadelphia chromosome by
conventional cytogenetics must have FISH or PCR performed for BCR/ABL to exclude
occult translocations

- Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if
adequate number of circulating blasts from peripheral blood; FISH testing for common
B-lineage ALL abnormalities including t(9;22) (BCR/ABL1), t(12;21) (ETS-variant gene 6
[ETV6]/runt-related transcription factor 1 [RUNX1]), t(1;19) (pre-B-cell leukemia
homeobox 1 [PBX1]/transcription factor 3 [TCF3]), +4,+10,+17, (centromeric
[Cen]4/Cen10/Cen17), t(11q23;var), (myeloid/lymphoid or mixed lineage leukemia [MLL]),
deletion (del)(9p) (cyclin-dependent kinase inhibitor 2A [CDKN2A]/Cen9), and t(14;var)
(immunoglobulin heavy chain [IGH] is encouraged); if there are few or no circulating
blasts and an adequate marrow sample cannot be obtained for cytogenetic analysis, the
patient may still enroll on the trial

- Patient must not have a concurrent active malignancy for which they are receiving
treatment

- Serum direct bilirubin < 2 mg/dl or serum total bilirubin =< 3; NOTE: the above
stipulation for normal hepatic function does not apply if liver dysfunction is due to
leukemia infiltration

- Serum creatinine < 2 mg/dl; NOTE: the above stipulation for normal hepatic function
does not apply if liver dysfunction is due to leukemia infiltration

- Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during
induction therapy phase or a written explanation for not undergoing HLA typing on the
flow sheet

- Patient must not have intercurrent organ damage or medical problems that will
jeopardize the outcome of therapy (i.e., psychiatric disorder, drug abuse, pregnancy)

- Patients with known human immunodeficiency virus (HIV) infection are eligible if they
meet all of the following criteria:

- No history of acquired immune deficiency syndrome (AIDS)-related complications
other than a history of low CD4+ T-cell count (< 200/mm^3) prior to initiation of
combination antiretroviral therapy; on study CD4+ T-cell count may not be
informative due to leukemia and should not be used as an exclusion criterion if
low

- Patient must be healthy on the basis of HIV disease with high likelihood of near
normal life span were it not for the leukemia

- Patient must have serum HIV viral load of < 200 copies/mm^3

- Patient must be on combination antiretroviral therapy with minimal
pharmacokinetic interactions with study therapy and minimal overlapping clinical
toxicity with protocol therapy

- Patient must not be receiving protease inhibitors or once daily formulations
containing cobicistat, stavudine, or on regimens containing stavudine or
zidovudine

- It is recommended to utilize a regimen of the integrase inhibitor, dolutegravir,
combined with either disoproxil fumarate/emtricitabine or dolutegravir combined
with tenofovir alafenamide/emtricitabine

- Patient must not have an antecedent hematologic disorder

- Patient must have no history of recent myocardial infarction (within three months),
uncontrolled congestive heart failure, or uncontrolled cardiac arrhythmia

- Patient must not have a history or presence of clinically relevant central nervous
system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe
brain injuries, dementia; Parkinson's disease, cerebellar disease, organic brain
syndrome, psychosis, or other significant CNS abnormalities

- Patient must have a normal cardiac ejection fraction by pretreatment multigated
acquisition scan (MUGA) or echocardiogram within 4 weeks prior to registration
(resting ejection fraction >= 40% or >= 5% increase with exercise), shortening
fraction by echocardiogram >= 24%, or to within the normal range of values for the
institution

- Patient must not have an active uncontrolled infection

- Women must not be pregnant or breast-feeding and must not become pregnant or
breastfeed during protocol therapy and for at least 3 months after protocol therapy;
woman of childbearing potential must abstain from sexual activity or be willing to use
2 highly effective forms of contraception throughout protocol therapy and for at least
an additional 3 months after the last dose of protocol-specified therapy; all females
of childbearing potential must have a blood test or urine study within 2 weeks prior
to registration to rule out pregnancy; a female of childbearing potential is any
woman, regardless of sexual orientation or whether they have undergone tubal ligation,
who meets the following criteria: has not undergone a hysterectomy or bilateral
oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive
months (i.e., has had menses at any time in the preceding 24 consecutive months)

- Men who have a female partner of childbearing potential must be willing to use 2
highly effective forms of contraception throughout protocol therapy and for at least
an additional 3 months after the last dose of protocol-specified therapy; men who have
a pregnant partner must be willing to use a condom during sexual activity throughout
protocol therapy and for 3 months after the last dose of protocol-specified therapy

- ECOG performance score 0-3

- Patient must have given written informed consent

- POST-INDUCTION THERAPY ELIGIBILITY CRITERIA (PRIOR TO INTENSIFICATION-STEP 2)

- ECOG performance status 0-2

- Patients must have achieved a CR or CRi

- Patients who have achieved a CR or CRi must have maintained peripheral blood evidence
of a CR or CRi

- Patient must be CNS (cerebrospinal fluid [CSF]) negative for leukemia

- Patients must have resolved any serious infectious complications related to induction

- Any significant medical complications related to induction must have resolved

- Obtained =< 48 hours prior to registration: Serum creatinine =< 2.0 mg/dl

- Obtained =< 48 hours prior to registration: Serum direct bilirubin < 2 mg/dL or serum
total bilirubin =< 3

- Obtained =< 48 hours prior to registration: Aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN)

- RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3

- Patients must have an ECOG performance status of 0-2

- Patients must have maintained peripheral blood evidence of a remission and must have a
CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy

- Patients must have resolved any serious infectious complications related to therapy

- Any significant medical complications related to therapy must have resolved

- Direct or total bilirubin < 1.5 x ULN (unless related to Gilbert's or Meulengracht's
syndrome); the values must be obtained within 48 hours prior to randomization

- Serum creatinine < 1.5 x ULN; the values must be obtained within 48 hours prior to
randomization

- Bone marrow aspirates must be submitted for centralized minimal residual disease (MRD)
assessment performed by the ECOG-ACRIN Leukemia Translational Research Laboratory

- MRD results will be reported to the submitting institution

- NOTE: FOR MRD ASSESSMENTS, AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION
SITE MUST BE SUBMITTED (THE NEEDLE CAN BE RE-DIRECTED THROUGH THE SAME SKIN
PUNCTURE SITE); ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE
FOR MRD TESTING; DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME
ASPIRATION SITE

- In B-lineage ALL, MRD levels in peripheral blood or from a dilute marrow
aspiration can be 300% lower, on average, than those in bone marrow at a given
time point; submitting a first pull from a separate aspiration site will ensure
that MRD determinations used in randomization and trial interpretation are
accurate

- NOTE: failure to submit bone marrow aspirates will result in a major
violation at the time of an audit

- CRITERIA FOR ALLOGENEIC TRANSPLANTATION

- A suitable donor must be identified; there are no restrictions on donor type and can
include a matched sibling, a matched or mismatched unrelated donor, a family haplotype
matched donor or a cord blood donor (single or double)

- Patients should meet the eligibility criteria for RANDOMIZATION TO BLINATUMOMAB OR NO
BLINATUMOMAB-STEP 3

- Patients must be considered reliable enough to comply with the medication regimen and
follow-up, and have social support necessary to allow this compliance

- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have an ECOG performance status
of 0-3

- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have maintained peripheral
blood evidence of a remission and must have a CR or CRi, confirmed on restaging BM
aspirate and biopsy

- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Patients must have resolved any serious
infectious complications related to therapy

- CRITERIA FOR MAINTENANCE THERAPY-STEP 4: Any significant medical complications related
to therapy must have resolved
We found this trial at
477
sites
Twin Falls, Idaho 83301
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Twin Falls, ID
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Daniel J. DeAngelo
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Eunice S. Wang
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Muthu Veeraputhiran
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Jonathan E. Kolitz
Phone: 516-734-8896
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Danielle A. Shafer
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Alison K. Conlin
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
?
mi
from
Yakima, WA
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
Principal Investigator: Julie D. Asch
Phone: 801-855-4100
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Rebecca B. Klisovic
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Henry K. Holland
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
22 South Greene Street
Baltimore, Maryland 21201
410-328-7904
Principal Investigator: Maria R. Baer
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Keith W. Pratz
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Mark B. Geyer
Phone: 212-639-5007
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Andrew P. Dalovisio
Phone: 225-761-5346
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: Andrew P. Dalovisio
Phone: 225-761-5346
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Principal Investigator: Krishna Gundabolu
Phone: 402-559-6941
?
mi
from
Bellevue, NE
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
?
mi
from
Bellevue, WA
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Alison K. Conlin
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
8901 Rockville Pike
Bethesda, Maryland 20889
(301) 295-4000
Principal Investigator: Clifton C. Mo
Phone: 301-319-2100
Walter Reed National Military Medical Center The Walter Reed National Military Medical Center is one...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Nikolaos Papadantonakis
Phone: 205-934-0220
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
?
mi
from
Boardman, OH
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
?
mi
from
Boone, IA
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Daniel J. DeAngelo
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Daniel J. DeAngelo
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
960 W Wooster St
Bowling Green, Ohio 43402
419-353-5419
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
?
mi
from
Bowling Green, OH
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Olga Derman
Phone: 718-904-2730
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Olga Derman
Phone: 718-904-2730
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Olga Derman
Phone: 718-904-2730
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 888-823-5923
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Alison K. Conlin
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
Calgary, Alberta
Principal Investigator: Kareem Jamani
Phone: 403-521-3433
?
mi
from
Calgary,
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
6501 E 2nd St
Casper, Wyoming 82609
(307) 235-5433
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
?
mi
from
Casper, WY
Click here to add this to my saved trials
1303 North Main Street
Cedar City, Utah 84721
(435) 868-5680
Principal Investigator: Julie D. Asch
Phone: 435-868-5680
Sandra L. Maxwell Cancer Center The Huntsman-Intermountain Cancer Center at Valley View Medical Center in...
?
mi
from
Cedar City, UT
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Alison K. Conlin
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Katarzyna J. Jamieson
Phone: 877-668-0683
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1200 West Harrison Stree
Chicago, Illinois 60607
(312) 996-4350
Principal Investigator: John G. Quigley
Phone: 312-355-3046
Univ of Illinois A major research university in the heart of one of the world's...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Chicago, Illinois 60608
Principal Investigator: Pam G. Khosla
Phone: 773-257-5960
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Wendy Stock
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Shira N. Dinner
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45230
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45211
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45202
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials